Literature DB >> 19051043

Pancreatic cancer expresses adiponectin receptors and is associated with hypoleptinemia and hyperadiponectinemia: a case-control study.

Maria Dalamaga1, Ilias Migdalis, Jessica L Fargnoli, Evangelia Papadavid, Erica Bloom, Nicholas Mitsiades, Konstantinos Karmaniolas, Nicolaos Pelecanos, Sofia Tseleni-Balafouta, Amalia Dionyssiou-Asteriou, Christos S Mantzoros.   

Abstract

Obesity and insulin resistance have been implicated in the etiology of pancreatic cancer (PC). Whether adiponectin and/or leptin, two adipocyte-secreted hormones important in metabolic regulation, are associated with PC pathogenesis and whether adiponectin receptors are expressed in PC remains unknown. In a hospital-based case-control study, we studied 81 cases with incident, histologically confirmed PC and 81 controls matched on gender and age between 2000 and 2007 to investigate the role of adiponectin and leptin adjusting for risk factors linked to PC. In a separate study, we also studied for the first time whether adiponectin receptors 1 and 2 are expressed in PC by studying 16 PC tumor tissue samples which were analyzed using immunohistochemistry. When subjects were divided into control-defined quartiles of adiponectin and leptin, lower leptin but higher adiponectin levels were associated with PC (p = 0.001 and p = 0.05 respectively) before and after controlling for age, gender, BMI, smoking status, alcohol consumption, history of diabetes, and family history of pancreatic cancer. Of the PC tumor tissue samples analyzed, 87.5% had positive or strong positive expression of AdipoR1 and 93.7% had positive or strong positive expression of AdipoR2. Further prospective studies are needed to determine whether the elevated adiponectin and low leptin levels reported in this study reflect compensatory changes during PC progression and thus can be used as markers for PC or whether they are causally implicated in PC.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 19051043      PMCID: PMC2720089          DOI: 10.1007/s10552-008-9273-z

Source DB:  PubMed          Journal:  Cancer Causes Control        ISSN: 0957-5243            Impact factor:   2.506


  40 in total

1.  Low adiponectin levels are associated with renal cell carcinoma: a case-control study.

Authors:  Themistoklis N Spyridopoulos; Eleni Th Petridou; Alkistis Skalkidou; Nick Dessypris; George P Chrousos; Christos S Mantzoros
Journal:  Int J Cancer       Date:  2007-04-01       Impact factor: 7.396

2.  Adiponectin and mortality in patients undergoing coronary angiography.

Authors:  Stefan Pilz; Harald Mangge; Britta Wellnitz; Ursula Seelhorst; Bernhard R Winkelmann; Beate Tiran; Bernhard O Boehm; Winfried März
Journal:  J Clin Endocrinol Metab       Date:  2006-08-15       Impact factor: 5.958

Review 3.  Drug Insight: the role of leptin in human physiology and pathophysiology--emerging clinical applications.

Authors:  Aoife M Brennan; Christos S Mantzoros
Journal:  Nat Clin Pract Endocrinol Metab       Date:  2006-06

Review 4.  Pancreatic adenocarcinoma.

Authors:  Wolfgang Schima; Ahmed Ba-Ssalamah; Claus Kölblinger; Christiane Kulinna-Cosentini; Andreas Puespoek; Peter Götzinger
Journal:  Eur Radiol       Date:  2006-10-05       Impact factor: 5.315

5.  Body mass index and pancreatic cancer risk: A meta-analysis of prospective studies.

Authors:  Susanna C Larsson; Nicola Orsini; Alicja Wolk
Journal:  Int J Cancer       Date:  2007-05-01       Impact factor: 7.396

6.  Adiponectin as a potential differential marker to distinguish pancreatic cancer and chronic pancreatitis.

Authors:  Ming-Chu Chang; Yu-Ting Chang; Ta-Chen Su; Wei-Shiung Yang; Chi-Ling Chen; Yu-Wen Tien; Po-Chin Liang; Shu-Chen Wei; Jau-Min Wong
Journal:  Pancreas       Date:  2007-07       Impact factor: 3.327

7.  Circulating adiponectin levels in relation to melanoma: a case-control study.

Authors:  C S Mantzoros; M Trakatelli; H Gogas; N Dessypris; A Stratigos; G P Chrousos; E Th Petridou
Journal:  Eur J Cancer       Date:  2007-05-23       Impact factor: 9.162

8.  Prediagnostic plasma C-peptide and pancreatic cancer risk in men and women.

Authors:  Dominique S Michaud; Brian Wolpin; Ed Giovannucci; Simin Liu; Barbara Cochrane; JoAnn E Manson; Michael N Pollak; Jing Ma; Charles S Fuchs
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2007-09-28       Impact factor: 4.254

Review 9.  Leptin and adipocytokines: bridging the gap between immunity and atherosclerosis.

Authors:  Giuseppe Matarese; Christos Mantzoros; Antonio La Cava
Journal:  Curr Pharm Des       Date:  2007       Impact factor: 3.116

Review 10.  Pancreatic cancer: diagnosis and management.

Authors:  Robert Freelove; Anne D Walling
Journal:  Am Fam Physician       Date:  2006-02-01       Impact factor: 3.292

View more
  50 in total

Review 1.  Obesity and pancreatic cancer: overview of epidemiologic evidence and biologic mechanisms.

Authors:  Paige M Bracci
Journal:  Mol Carcinog       Date:  2012-01       Impact factor: 4.784

2.  Case-control study of diabetes-related genetic variants and pancreatic cancer risk in Japan.

Authors:  Sawako Kuruma; Naoto Egawa; Masanao Kurata; Goro Honda; Terumi Kamisawa; Junko Ueda; Hiroshi Ishii; Makoto Ueno; Haruhisa Nakao; Mitsuru Mori; Keitaro Matsuo; Satoyo Hosono; Shinichi Ohkawa; Kenji Wakai; Kozue Nakamura; Akiko Tamakoshi; Masanori Nojima; Mami Takahashi; Kazuaki Shimada; Takeshi Nishiyama; Shogo Kikuchi; Yingsong Lin
Journal:  World J Gastroenterol       Date:  2014-12-14       Impact factor: 5.742

Review 3.  Adiponectin as a Potential Therapeutic Target for Prostate Cancer.

Authors:  Hanuma Kumar Karnati; Manas Kumar Panigrahi; Yazhou Li; David Tweedie; Nigel H Greig
Journal:  Curr Pharm Des       Date:  2017       Impact factor: 3.116

4.  A prospective study of plasma adiponectin and pancreatic cancer risk in five US cohorts.

Authors:  Ying Bao; Edward L Giovannucci; Peter Kraft; Meir J Stampfer; Shuji Ogino; Jing Ma; Julie E Buring; Howard D Sesso; I-Min Lee; John Michael Gaziano; Nader Rifai; Michael N Pollak; Barbara B Cochrane; Virginia Kaklamani; Jennifer H Lin; Joann E Manson; Charles S Fuchs; Brian M Wolpin
Journal:  J Natl Cancer Inst       Date:  2012-12-14       Impact factor: 13.506

Review 5.  Adipocytes: impact on tumor growth and potential sites for therapeutic intervention.

Authors:  Simona Hefetz-Sela; Philipp E Scherer
Journal:  Pharmacol Ther       Date:  2013-01-24       Impact factor: 12.310

6.  Comparison of adiponectin concentration between pancreatic cancer and colorectal cancer.

Authors:  Jean Marc Phelip; Serban Bageacu; Mathieu Baconnier; Gabriele Barabino; Emilie Del Tedesco; Pierre Yves Benhamou; Xavier Roblin
Journal:  J Gastrointest Oncol       Date:  2011-12

7.  Adiponectin receptor 2 is negatively associated with lymph node metastasis of colorectal cancer.

Authors:  Masaya Hiyoshi; Nelson H Tsuno; Kensuke Otani; Kazushige Kawai; Takeshi Nishikawa; Yasutaka Shuno; Kazuhito Sasaki; Kumiko Hongo; Manabu Kaneko; Eiji Sunami; Koki Takahashi; Hirokazu Nagawa; Joji Kitayama
Journal:  Oncol Lett       Date:  2012-02-07       Impact factor: 2.967

8.  Interplay of adipokines and myokines in cancer pathophysiology: Emerging therapeutic implications.

Authors:  Maria Dalamaga
Journal:  World J Exp Med       Date:  2013-08-20

Review 9.  Adiponectin in insulin resistance: lessons from translational research.

Authors:  Florencia Ziemke; Christos S Mantzoros
Journal:  Am J Clin Nutr       Date:  2009-11-11       Impact factor: 7.045

Review 10.  Classic and Novel Adipocytokines at the Intersection of Obesity and Cancer: Diagnostic and Therapeutic Strategies.

Authors:  Nikolaos Spyrou; Konstantinos I Avgerinos; Christos S Mantzoros; Maria Dalamaga
Journal:  Curr Obes Rep       Date:  2018-12
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.